Doing difficult but right things: WuXi AppTec (02359) provides support for 24 GLP-1 drugs to meet the most urgent clinical needs.

On January 14, 2026, WuXi AppTec (603259.SH, 02359) announced the latest progress of its GLP-1 drug pipeline at the 44th Annual JPMorgan Healthcare Conference (JPM Conference). The company stated that it is currently providing support for 24 GLP-1 drugs. According to data disclosed by WuXi AppTec, as of now, the company is developing 24 GLP-1 drugs, covering two types of technologies: small molecules and peptides. Of these, 15 have entered phase two and three clinical trial stages. Based on the pipeline progress, the company is expected to occupy approximately 25% of the global GLP-1 related market share. The persistent shortage of GLP-1 drugs in recent years may highlight inadequacies in the core drug supply chain. The demand for these drugs is experiencing exponential growth, which is historically rare. Some pharmaceutical companies, when faced with shortages, have successfully overcome challenges by mobilizing internal resources and efficiently outsourcing to selected external partners through flexible and expanding production methods. As a key participant in the global core drug supply chain, WuXi AppTec emphasizes that its capacity construction has been planned ahead. The company recently completed the construction of a 10,000 liter solid-phase synthesis reactor, aiming to strengthen large-scale production capacity to support the urgent needs of partners and clinical trials. With the increasing availability of GLP-1 drugs, the treatment landscape for obesity and related metabolic diseases is expected to further reshape, potentially marking the beginning of a "treatment revolution".